# Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

> **NCT02633943** · — · ACTIVE_NOT_RECRUITING · sponsor: **Genetix Biotherapeutics Inc.** · enrollment: 66 (actual)

## Conditions studied

- Transfusion-dependent Beta-Thalassemia

## Interventions

- **OTHER:** Safety and efficacy assessments

## Key facts

- **NCT ID:** NCT02633943
- **Lead sponsor:** Genetix Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-01
- **Primary completion:** 2035-11
- **Final completion:** 2035-11
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633943, "Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02633943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*